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www.sciencedirect.comEDITORIALGlaucoma, challenges and opportunitiesWe are proud to present our readership with this Glaucoma
Update of the Saudi Journal of Ophthalmology. A variety of
glaucomatologists and researchers, leaders in their ﬁeld, have
made it possible to assemble this volume with outstanding re-
views. The different topics reﬂect the diverse challenges and
progress presently occurring in Glaucoma.
(1) There are several reviews on surgical approaches:1319-4
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doi:10Children present unique and multiple surgical chal-
lenges. They tend to scar down faster and fail regular ﬁl-
tering surgery but there is reluctancy to use
antimetabolites during this susceptible age. Dr. Coleman
et al. draw from a long experience with Ahmed implants
and this type of glaucoma since their ﬁrst publication
(Coleman et al., 1997). They review current knowledge
regarding indications, long term results and complica-
tions of this kind of implant for these patients. Ahmed
implant with its valve mechanism seems to offer a surgi-
cal option which in experienced hands is relatively safe
because of less hypotony complications.
Canaloplasty is a relatively new procedure, among sev-
eral, attempting to lower intraocular pressure with less
complications than those observed with trabeculectomy
(Mosaed et al., 2009). Dr. Al Khaimi et al. provide us
with an update of its results and complications. With
the help of a ﬂashing beacon of light and high resolution
UBM this procedure accomplishes a much more con-
trolled 360 cannulation of Schlemm’s canal than
obtained before, and it is combined with viscodilation
and deep sclerectomy. It may still be early to deﬁne what
the role of such a procedure will be among the glaucoma534 ª 2011 King Saud University. Production and hosting by
r B.V. All rights reserved.
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Production and hosting by Elsevierarmamentarium but such efforts improve our under-
standing of the involved anatomy of Schlemm’s canal
and collector channels and it shows a ﬂurry of interest
in ﬁnding a better solution to traditional ﬁltering proce-
dures which depend on a bleb (Francis et al., 2011).
Angle closure glaucoma mechanism is turning out to
be much more complex than originally thought of
(Nongpiur et al., 2011). Dr. Eid focuses his review on
the impact of removing the lens in patients with this con-
dition at different stages. Clear lens extraction, although
controversial, is being utilized by some in patients with
no other problem than a refractive error. Some argue
that it is more valid to use this approach in patients with
actual disease such as primary angle closure or primary
angle closure glaucoma with a clear lens and current
trials are on their way (Azuara-Blanco et al., 2011).(2) In the area of genetics researchLOXL1 gene mutation was a landmark discovery in
genetics and secondary open angle glaucoma exploration
with a large genome wide association study (Thorleifsson
et al., 2007). Although initially described in Scandinavia,
repeated studies have shown its presence worldwide and
it is considered a major genetic risk factor for Pseudoex-
foliation syndrome and Pseudoexfoliation glaucoma. It
was hypothesized that if this mutation was responsible
for the aggregation of the Pseudoexfoliation material
and if it was possible to avoid this aggregation, then
Pseudoexfoliation glaucoma could be the ﬁrst glaucoma
that could be prevented. Dr. Allingham et al. summarize
the current status of the research done around the world
regarding this gene and highlight some of the differences
regarding the occurrence of this gene and speciﬁc muta-
tions among different populations including a recent
genetic study in Saudi Arabia (Abu-Amero et al.,
2010). This topic is particularly relevant for this region
because pseudoexfoliation prevalence has been reported
among the highest in Saudi Arabia (Summanenand To¨n-
jum, 1988).
Gene therapy seems to be a new frontier not only in
ophthalmology but also in medicine. Dr. Borras et al.
314 Editorialclearly describe and summarize different strategies with
regard to genetic treatment possibilities which seem
feasible and promising. Although steroid induced glau-
coma has been extensively studied since long ago (Kayes
and Becker, 1969). Their team has pioneered gene ther-
apy treatments in a reproducible animal model of steroid
induced glaucoma (Gerometta et al., 2010). Their work
could eventually lead to the treatment of steroid glau-
coma and in the mean time provide us with a better
understanding of glaucoma mechanisms in general.
Dr. Taylor et al. provide us with a comprehensive
review of mitochondrial DNA abnormalities encoun-
tered in the eye. The optic nerve has one of the highest
mitochondrial concentration in the human body and
there has been recent interest by our group (Abu-Amero
et al., 2006) and others with respect to mitochondrial
DNA abnormalities in glaucoma (Kong et al., 2009).
(3) Concerning optic nerve imaging, Dr. Ritch et al. bring
us a comprehensive review of ways to image the lamina
cribrosa including some of the newest applications of
spectral domain optical coherence tomography with
beautiful images. This is important because recent liter-
ature suggests that in some of those patients with glau-
coma progression in spite of apparently well controlled
IOP, ﬂuctuations between intracranial pressure and
intraocular pressure could be responsible (Wostyn
et al., 2011). It is an intriguing hypothesis and something
deﬁnitely worth investigating more but in the mean time
their investigations are already shedding new light over
the ﬁne, in vivo, morphology of such an important part
of the optic nerve.
(4) With regard to glaucoma epidemiology in the region,
particular features of glaucoma distribution are exam-
ined by a systematic review of a large number of glau-
coma patients in one of the main referral ophthalmic
centers in Saudi Arabia, by Dr. Obeidan et al. These
results suggest a pattern quite different from those
observed in the Western hemisphere. There was a pre-
dominance of angle closure glaucoma among primary
glaucomas and of pseudoexfoliation glaucoma (associ-
ated with a signiﬁcant proportion of angle closure)
among secondary glaucomas. Although selection bias
is likely in a referral center, further population studies
are warranted as suggested by the author. The angle clo-
sure predominance may be similar to that reported in
Asiatic groups (Yip and Foster, 2006). The high fre-
quency of pseudoexfoliation glaucoma and its angle clo-
sure component deserves further study.
(5) Regarding patient care, Dr. Spaeth et al. highlight the
fact that even though we may have a short time during
our encounter with a glaucoma patient we should prior-
itize and concentrate on what really matters to optimize
the use of such time. That we should remember to listen
to the patient ﬁrst and address his/her concerns and that
a detailed and systematic examination of the disc is vital
to establish the likelihood and stage of the disease. He
designed the use of the Disc Likelihood Damage Scale
classiﬁcation of the disc for this purpose (Spaeth et al.,
2002), raising the important points that it is not enough
to describe a disc with Cup to disc ratio and that this canbe deceiving when the size of the disc is not taken into
account as well as the area of thinning of the neuroreti-
nal rim. He also emphasizes on the fact that we should
not treat just a number but must take into account the
whole person including the quality of life with or with-
out medications, chances of the disease to produce dis-
ability in that particular person and to tailor the level
of treatment according to whether or not we believe that
the disease might cause signiﬁcant disability during the
expected life of such a person.
(6) And in the area of medical management of glaucoma,
Dr. Traverso et al. address the issue of local side effects
and decreased compliance, not caused by the anti glau-
coma active ingredients themselves but the vehicle or
preservative substances associated with them. Poor com-
pliance has been recognized since long as a problem in
glaucoma treatment (Bloch et al., 1977). Recent medica-
tions attempt to address this problem by offering preser-
vative free or less toxic preservatives aiming to improve
tolerability in addition to the usually sought lowering of
intraocular pressure effect.
It is a privilege to be witnessing the exploration of new fron-
tiers in so many different areas in glaucoma research. Re-
assessing old paradigms and turning challenges into opportu-
nities hopefully will beneﬁt our patients, our primary and ﬁnal
concern.
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